NCT05344625View on ClinicalTrials.gov

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions
Cancer-related Problem/ConditionDepressive SymptomsAnxiety Disorders
Interventions
DRUG

Ketamine 100 MG/ML

Ketamine Assisted Psychotherapy

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER

NCT05344625 - Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress | Biotech Hunter | Biotech Hunter